Ciforadenant Has Promising Anti-tumor Activity in mCRPC, Early Data Show

Ciforadenant Has Promising Anti-tumor Activity in mCRPC, Early Data Show
Treatment with Corvus Pharmaceuticals' ciforadenant (CPI-444), alone or in combination with Tecentriq (atezolizumab), is well tolerated and showed promising anti-tumor activity in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients, early data from a Phase 1b/2 clinical trial suggest. Lawrence Fong, MD, leader of the cancer immunotherapy program at the  Helen Diller Family Comprehensive Cancer Center at the University of California San Francisco, presented the findings at the American Society of Clinical Oncology (ASCO) 2020 Genitourinary Cancers Symposium. The poster presentation was titled, “Adenosine Receptor Blockade with Ciforadenant ± Atezolizumab in Advanced Metastatic Castration Resistant Prostate Cancer (mCRPC).” CD73 is a cell surface protein that is often elevated in metastatic prostate cancer patients and helps the tumor grow by dampening anti-tumor immune responses. It does so by increasing the levels of adenosine, an immunosuppressive metabolite. Adenosine works much like other immune checkpoints, such as PD-L1 and CD47, signaling through a receptor on immune cells and starting a chain of events that "tell" immune cells to leave the cancer unharmed. Therapies blocking these molecules on cancer cells or their receptors on immune cells — broadly called immune checkpoint inhibitors — are now a mainstay in cancer therapy. Researchers at Corvus have been developing molecules that block adenosine signaling in multiple cancers. Ciforadenant, in particular, is an inhibitor of the adenosine A2A receptor (A2AR) on immune cells. The investigational therapy is being studied, alone and in combination with Genentech’s Tecentriq, in people with renal cell cancer and mCRPC patients in a randomized, open-label
Subscribe or to access all post and page content.